Literature DB >> 11427587

Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.

P A Cane1, A de Ruiter, P Rice, M Wiselka, R Fox, D Pillay.   

Abstract

This work reports the variability of human immunodeficiency virus type 1 (HIV-1) protease from treated and untreated patients infected with HIV-1 subtype C in the United Kingdom. The most common primary mutation observed in treated patients was L90M. D30N, M46I, V82A/F, and I84V were seen rarely. M36I and I93L mutations were observed in nearly all samples from both treated and untreated patients and so cannot be considered as resistance-associated mutations in this subtype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427587      PMCID: PMC88203          DOI: 10.1128/JCM.39.7.2652-2654.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Recombinant strains of HIV type 1 in the United Kingdom.

Authors:  K L Barlow; I D Tatt; P A Cane; D Pillay; J P Clewley
Journal:  AIDS Res Hum Retroviruses       Date:  2001-03-20       Impact factor: 2.205

2.  Detection of drug resistance associated mutations in HIV primary infection within the UK.

Authors:  D Pillay; P A Cane; J Shirley; K Porter
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

3.  Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

Authors:  R W Shafer; T K Chuang; P Hsu; C B White; D A Katzenstein
Journal:  AIDS Res Hum Retroviruses       Date:  1999-01-01       Impact factor: 2.205

4.  Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

Authors:  M J Kozal; N Shah; N Shen; R Yang; R Fucini; T C Merigan; D D Richman; D Morris; E Hubbell; M Chee; T R Gingeras
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

5.  At least five HIV-1 sequence subtypes (A, B, C, D, A/E) occur in England.

Authors:  C Arnold; K L Barlow; J V Parry; J P Clewley
Journal:  AIDS Res Hum Retroviruses       Date:  1995-03       Impact factor: 2.205

6.  Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States.

Authors:  P J Weidle; C E Ganea; K L Irwin; D Pieniazek; J P McGowan; N Olivo; A Ramos; C Schable; R B Lal; S D Holmberg; J A Ernst
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

7.  Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.

Authors:  D Pieniazek; M Rayfield; D J Hu; J Nkengasong; S Z Wiktor; R Downing; B Biryahwaho; T Mastro; A Tanuri; V Soriano; R Lal; T Dondero
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

8.  High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland.

Authors:  J Böni; H Pyra; M Gebhardt; L Perrin; P Bürgisser; L Matter; W Fierz; P Erb; J C Piffaretti; E Minder; P Grob; J J Burckhardt; M Zwahlen; J Schüpbach
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

9.  Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.

Authors:  L Vergne; M Peeters; E Mpoudi-Ngole; A Bourgeois; F Liegeois; C Toure-Kane; S Mboup; C Mulanga-Kabeya; E Saman; J Jourdan; J Reynes; E Delaporte
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

10.  The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention.

Authors:  D J Hu; T J Dondero; M A Rayfield; J R George; G Schochetman; H W Jaffe; C C Luo; M L Kalish; B G Weniger; C P Pau; C A Schable; J W Curran
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

View more
  22 in total

1.  Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.

Authors:  Roxana M Coman; Arthur Robbins; Maureen M Goodenow; Robert McKenna; Ben M Dunn
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-03-30

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

Authors:  A Waléria-Aleixo; A N Martins; M B Arruda; R M Brindeiro; R M Da-Silva; F F Nobre; D B Greco; A Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

4.  Active-site mutations in the South african human immunodeficiency virus type 1 subtype C protease have a significant impact on clinical inhibitor binding: kinetic and thermodynamic study.

Authors:  Salerwe Mosebi; Lynn Morris; Heini W Dirr; Yasien Sayed
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

Review 5.  Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Authors:  Robert W Shafer; Soo-Yon Rhee; Diane E Bennett
Journal:  Antivir Ther       Date:  2008

6.  Web resources for HIV type 1 genotypic-resistance test interpretation.

Authors:  Tommy F Liu; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

7.  Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.

Authors:  Luis M F Gonzalez; Rodrigo M Brindeiro; Renato S Aguiar; Helena S Pereira; Celina M Abreu; Marcelo A Soares; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

Authors:  Jorge L Martinez-Cajas; Nitika P Pai; Marina B Klein; Mark A Wainberg
Journal:  J Int AIDS Soc       Date:  2009-06-30       Impact factor: 5.396

9.  Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric - shape similarity scoring function.

Authors:  Sergey Shityakov; Thomas Dandekar
Journal:  Bioinformation       Date:  2010-01-20

10.  Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing.

Authors:  Soo-Yon Rhee; Tommy Liu; Jaideep Ravela; Matthew J Gonzales; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.